Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
Lens on patient care & allied health workforce across settings
The CEO of Allied Health Professions Australia (AHPA), Bronwyn Morris-Donovan spoke with Australian Health Journal about the following:
The structure and priorities for AHPA
The setting and disciplines in Allied Health
Allied Health representation in the Strengthening Medicare Task Force
Importance of a data strategy and interoperability in delivery of allied health services
Key allied health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Career advice from an Emergency Physician in Research
Associate Professor Viet Tran, an experienced emergency physician at the Royal Hobart Hospital. He spoke with Australian Health Journal about the crucial role of emergency departments as the frontline of hospitals, providing immediate care, diagnosis, resuscitation, and serving as a safety net for the healthcare system. Prof. Tran highlights the importance of understanding the daily responsibilities and core aspects of a specialty when choosing a medical career.
-
Startup Advances Biosensing
Melbourne based Nutromics is looking to solve some of the biggest healthcare challenges, by delivering on a mission to revolutionise precision medicine with Continuous Molecular Monitoring (CMM). Nutromics is developing biosensor technology integrated into a small and unobtrusive wearable smart patch.The software solution aims to be flexible and designed to connect with mobile and web solutions for integration with consumer health software and hospital platforms.
